Daratumumab, given on its own, could be a treatment for adults with hard to treat cold agglutinin disease (CAD), with more than half of the patients in a small study in Europe responding well to the therapy. The findings add to previous reports about the successful use of…
Cold agglutinin disease (CAD) secondary to a blood cancer was the most likely diagnosis for an elderly woman in Washington, D.C., despite a negative result on a diagnostic test for CAD known as a direct Coombs test, a case report shows. The test assesses whether red blood cells…
Most children and adolescents with autoimmune hemolytic anemia (AIHA) — a group of rare conditions that includes cold agglutinin disease (CAD) — respond well to the recommended first-line treatment for adult patients, a study found. The retrospective, single-center study in Brazil found that only a minority of pediatric AIHA…
Infection with SARS-CoV-2, the virus that causes COVID-19, worsened symptoms of cold agglutinin disease (CAD) in a 71-year-old man in whom the autoimmune disease had been stable, a U.S. study reports. This case highlights the need for clinicians to be “mindful of potential preexisting … conditions, particularly [blood-related] diseases,…
Initial results from a planned proof-of-concept clinical trial testing Annexon Biosciences’ treatment candidate ANX1502 in people with cold agglutinin disease (CAD) are expected in the second half of the year. “We anticipate clinical proof-of-concept data from our novel oral inhibitor ANX1502 later in the year,” Douglas Love, president…
Cold agglutinin disease (CAD) secondary to an infection with the Epstein-Barr virus led to a blocked vein due to blood clots in a young girl in Turkey, prolonging her hospital stay, a case study shows. The report, “A Rare Case Presentation: EBV-related Cold Agglutinin Disease and Venous Thrombosis,”…
People with cold agglutinin disease (CAD) who were on Enjaymo (sutimlimab-jome) during clinical trials produced antibodies in response to COVID-19 vaccination, suggesting their ability to mount an immune response was not impaired, a recent study reports. In patients with a waning immune response, a booster dose was enough…
Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) have stopped the clinical development of the experimental therapy pegcetacoplan for cold agglutinin disease (CAD). The decision, which includes discontinuing a Phase 3 clinical trial of the therapy in adults, was based on a realignment of the companies’ priorities in…
Rituximab does not seem to increase the risk for severe outcomes compared with other cold agglutinin disease (CAD) treatments in people who have the disease and COVID-19, according to a review study. “Nonetheless, caution is advised when using rituximab in CAD patients with COVID-19 and underlying [autoimmune] conditions…
A young boy in Portugal developed cold agglutinin disease (CAD) and an inflammatory condition called hemophagocytic lymphohistiocytosis (HLH) secondary to an infection with the Epstein-Barr virus, which can cause infectious mononucleosis, or mono. The boy recovered fully after being treated with corticosteroids, a type of anti-inflammatory and immunosuppressive medication,…
Get regular updates to your inbox.